Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Investigating Liver Cancer Pathogenesis Using Patient-Derived Organoids
Published on: August 18, 2023
Theranostic application of 131I-labeled anti-glypican-3 antibody for targeted radioimmunotherapy in hepatocellular
Ming-Hui Yang1, Kuo-Pin Chuang2, Hsin-Rou Liang3
1Division of General and Digestive Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, 807, Taiwan.
Abstract:
Hepatocellular carcinoma (HCC) is a highly lethal malignancy and a leading cause of cancer-related mortality worldwide, largely due to its asymptomatic progression and the limited therapeutic efficacy available for advanced stages. Glypican-3 (GPC3), a membrane-bound heparan sulfate proteoglycan, is overexpressed in approximately 70-80% of HCC cases while remaining absent in healthy liver tissue, making it an ideal theranostic target. In this study, we developed a novel 131I-labeled anti-GPC3 antibody. This radiopharmaceutical was synthesized with a high labeling yield (~93%) and demonstrated robust in vitro stability (with >81% radiochemical purity retained at 120 h). In vitro MTT assays revealed dose-dependent cytotoxicity, with cell viability significantly reduced to 27.7% at a dose of 6 μCi. In vivo evaluation in a spontaneous HCC mouse model confirmed strong GPC3 expression restricted specifically to tumor tissues. Biodistribution analysis further revealed preferential tumor accumulation (~1.3% injected dose per gram) with minimal radioactivity in non-target organs. Collectively, these findings demonstrate the feasibility and therapeutic potential of 131I-GPC3 as a targeted theranostic radiopharmaceutical for HCC and other GPC3-expressing malignancies.
Related Concept Videos
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Labeling Emotion
Waterproofing and Anti-Bacterial Admixtures in Concrete
Waterproofing admixtures render concrete hydrophobic,...
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.

